May 2025 - Page 15 of 17

Release – V2X Delivers First Quarter Results and Reaffirms Full-Year Guidance

Posted on May 5, 2025May 6, 2025 by aweinsoff@channelchek.com

Research News and Market Data on VVX

May 05, 2025

Download(opens in new window)

First Quarter Highlights

Revenue of $1.02 billion with +10% y/y growth in Indo-Pacific region
Net income of $8.1 million; Adjusted net income¹ of $31.5 million, up 10% y/y
Adjusted EBITDA¹ of $67.0 million, with a margin of 6.6%
Diluted EPS of $0.25; Adjusted diluted EPS¹ of $0.98, up 9% y/y
Enhanced capital structure to generate interest expense savings and cash flow
Notable progress on new Foreign Military and International Sales opportunities

RESTON, Va., May 5, 2025 /PRNewswire/ — V2X, Inc. (NYSE:VVX) announced first quarter 2025 financial results.

“The overall trends in our market remain positive and are being driven by customer requirements to improve deterrence, enhance readiness, and strengthen national security,” said Jeremy C. Wensinger, President and Chief Executive Officer. “We are performing well as V2X possesses the unique full lifecycle, mission driven solutions to deliver on these requirements. The V2X value proposition is being recognized by customers and is demonstrated by our recent wins and extensions, which provide substantial visibility for the next several years.”

Mr. Wensinger continued, “V2X is in an enviable position with strong visibility, differentiated capabilities, and a robust geographic footprint. We are capitalizing on this position by increasing bid velocity. Additionally, the foreign military sales and international markets continue to represent a large and growing addressable opportunity to deliver more solutions across locations in which we already operate. These customers know V2X, they trust V2X, and see the benefit of our solutions. Our focused engagement strategy and visible presence is yielding substantial traction on several nearer-term opportunities that align exactly to our core capabilities.”

Mr. Wensinger concluded, “We continue to execute in a dynamic market, bringing the whole of V2X to meet our customers critical mission requirements. It’s our employees that make this possible and I’d like to recognize their commitment and contributions.”

First Quarter 2025 Results

“V2X reported revenue of $1.02 billion in the quarter, with 10% year-over-year growth in the Indo-Pacific region,” said Shawn Mural, Senior Vice President and Chief Financial Officer. “We are pleased with our performance and start to the year, particularly in light of the overall market environment. We remain on track to achieve our commitments and are confident in the strength and resiliency of our business model that generates strong, predictable cash flow.”

“For the quarter, the Company reported operating income of $34.3 million and adjusted operating income¹ of $61.5 million. V2X delivered adjusted EBITDA¹ of $67.0 million, with a margin of 6.6%. Net income for the quarter was $8.1 million dollars, up from $1.1 million dollars from the prior year. Adjusted net income¹ was $31.5 million dollars, increasing 10% year-over-year. First quarter GAAP diluted EPS was $0.25. Adjusted diluted EPS¹ for the quarter was $0.98, increasing 9% year-over-year.”

Mr. Mural continued, “During the quarter we continued to demonstrate our steadfast commitment to increasing shareholder value by making further enhancements to our capital structure. Our strong fundamental profile and consistent financial performance created a compelling opportunity to reprice and extend both our revolver and Term Loan A.”

Reaffirming 2025 Guidance

Mr. Mural concluded, “The trends and demand signals in our business remain positive and we believe our strategy, visibility, and targeted growth opportunities will yield value creation. Given our performance in the first quarter and current trends, the Company is reaffirming guidance for 2025.”

Guidance is as follows:

$ millions, except for per share amounts	2025 Guidance		2025 Mid-Point
Revenue	$4,375	$4,500	$4,438
Adjusted EBITDA¹	$305	$320	$313
Adjusted Diluted Earnings Per Share¹	$4.45	$4.85	$4.65
Adjusted Net Cash Provided by Operating Activities¹	$150	$170	$160

The Company is not providing a quantitative reconciliation with respect to the foregoing forward-looking non-GAAP measures in reliance on the “unreasonable efforts” exception set forth in SEC rules because certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. For example, unusual, one-time, non-ordinary, or non-recurring costs, which relate to M&A, integration and related activities cannot be reasonably estimated. Forward-looking statements are based upon current expectations and are subject to factors that could cause actual results to differ materially from those suggested here, including those factors set forth in the Safe Harbor Statement below.

First Quarter Conference Call

Management will conduct a conference call with analysts and investors at 4:30 p.m. ET on Monday, May 5, 2025. U.S.-based participants may dial in to the conference call at 877-300-8521, while international participants may dial 412-317-6026. A live webcast of the conference call as well as an accompanying slide presentation will be available here: https://app.webinar.net/0pq4wxEAbDQ

A replay of the conference call will be posted on the V2X website shortly after completion of the call and will be available for one year. A telephonic replay will also be available through May 19, 2025, at 844-512-2921 (domestic) or 412-317-6671 (international) with passcode 10198194.

Presentation slides that will be used in conjunction with the conference call will also be made available online in advance on the “investors” section of the company’s website at https://gov2x.com. V2X recognizes its website as a key channel of distribution to reach public investors and as a means of disclosing material non-public information to comply with its obligations under the U.S. Securities and Exchange Commission (“SEC”) Regulation FD.

¹ See “Key Performance Indicators and Non-GAAP Financial Measures” for descriptions and reconciliations.

About V2X
V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.

Investor Contact	Media Contact
Mike Smith, CFA	Angelica Spanos Deoudes
IR@goV2X.com	Communications@goV2X.com
719-637-5773	571-338-5195

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 (the “Act”): Certain material presented herein includes forward-looking statements intended to qualify for the safe harbor from liability established by the Act.

Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “could,” “potential,” “continue” or similar terminology. These statements are based on the beliefs and assumptions of the management of the Company based on information currently available to management. Forward-looking statements in this press release, include, but are not limited to our future performance and capabilities; all of the statements and items listed under “Reaffirming 2025 Guidance” above and other assumptions contained therein for purposes of such guidance; our belief that prior performance provides substantial visibility for future performance; market trends; our expectations that the foreign military sales and international markets represent a large and growing addressable opportunity; and our belief that our strategy, visibility, and targeted growth opportunities provide substantial opportunities for value creation.

These forward-looking statements are not guarantees of future performance, conditions, or results, and involve a number of known and unknown risks, uncertainties, assumptions, and other important factors, many of which are outside our management’s control, which could cause actual results to differ materially from the results discussed in the forward-looking statements. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Company’s historical experience and our present expectations or projections. For a discussion of some of the risks and uncertainties that could cause actual results to differ from such forward-looking statements, see the risks and other factors detailed from time to time in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other filings with the SEC.

View the full release here.

Release – MAIA Biotechnology Announces $1.08 Million Private Placement

Posted on May 5, 2025May 6, 2025 by aweinsoff@channelchek.com

Research News and Market Data on MAIA

May 05, 2025 4:05pm EDT Download as PDF

CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 719,999 shares of common stock at a purchase price of $1.50 per share, in a private placement to accredited investors and certain Company directors. Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $2.05 per share, which price represents the greater of the book or market value of the stock on the date the definitive agreements were executed (subject to customary adjustments as set forth in the warrants). The warrants are exercisable commencing six months following issuance and have a term of five years from the initial exercise date. The securities being sold to the Company directors participating in the offering are being issued pursuant to the Company’s 2021 Equity Incentive Plan. The private placement is expected to close on or about May 7, 2025, subject to the satisfaction of customary closing conditions.

The gross proceeds from the offering are expected to be approximately $1.08 million, prior to offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for to fund the starting cost for Part C of the Phase II trial THIO -101 and for working capital.

The securities described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250505358174/en/

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

Source: MAIA Biotechnology, Inc.

Released May 5, 2025

Noble Capital Markets Emerging Growth Virtual Equity Conference 2025 – Presentation Replays

Posted on May 5, 2025June 6, 2025 by cpatches

Investor / Attendee Registration

Watch the replays from the Noble Capital Markets Emerging Growth Virtual Equity Conference. Replays are available to Channelchek registered members. Registration is free and easy. Simply click the Join button in the upper right to get started.

Day 1 Replays

**Connect Biopharma (CNTB)**
**Watch the Replay**

**Charles River Associates (CRAI)**
**Watch the Replay**

**Eledon Pharmaceuticals (ELDN)**
**Watch the Replay**

**Euroseas (ESEA)**
**Watch the Replay**

**The ONE Group (STKS)**
**Watch the Replay**

**Steelcase (SCS)**
**Watch the Replay**

**GoHealth (GOCO)**
**Watch the Replay**

**Unicycive Therapeutics (UNCY)**
**Watch the Replay**

**Townsquare Media (TSQ)**
**Watch the Replay**

**Greenwich LifeSciences (GLSI)**
**Watch the Replay**

**CBL International (BANL)**
**Watch the Replay**

**Twin Hospitality Group (TWNP)**
**Watch the Replay**

**Flushing Financial (FFIC)**
**Watch the Replay**

Day 2 Replays

**Sigma Lithium (SGML)**
**Watch the Replay**

**BioLargo Inc. (BLGO)**
**Watch the Replay**

**SKYX Platforms (SKYX)**
**Watch the Replay**

**Titan International (TWI)**
**Watch the Replay**

**Superior Group of Companies** **Watch the Replay**

**CoreCivic (CXW)**
**Watch the Replay**

**Brilliant Earth Group (BRLT)**
**Watch the Replay**

**Cocrystal Pharma (COCP)**
**Watch the Replay**

**Sky Harbour Group (SKYH)**
**Watch the Replay**

**FAT Brands (FAT)**
**Watch the Replay**

**Lottery.com (LTRY)**
**Watch the Replay**

**SBC Medical Group (SBC)**
**Watch the Replay**

**Kalaris Therpeutics (KLRS)**
**Watch the Replay**

**Nutriband (NTRB)**
**Watch the Replay**

Participating in 1×1 Meetings Only

Release – SelectQuote to Release Fiscal Third Quarter 2025 Earnings on May 12

Posted on May 5, 2025May 5, 2025 by aweinsoff@channelchek.com

Research News and Market Data on SLQT

05/05/2025

OVERLAND PARK, Kan.–(BUSINESS WIRE)– SelectQuote, Inc. (NYSE: SLQT), a leading distributor of Medicare insurance policies and owner of a rapidly growing Healthcare Services platform, today announced it will release its third quarter 2025 financial results before market open on Monday, May 12, 2025. Chief Executive Officer, Tim Danker, and Chief Financial Officer, Ryan Clement, will host a conference call on the day of the release (May 12, 2025) at 8:30 am ET to discuss the results.

To register for this conference call, please use this link: https://registrations.events/direct/Q4I54780976.

After registering, a confirmation will be sent via email, including dial in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. The event will also be webcasted live via our investor relations website https://ir.selectquote.com/investor-home/default.aspx or via this link.

About SelectQuote:

Founded in 1985, SelectQuote (NYSE: SLQT) pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies, allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote’s success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads. Today, the Company operates an ecosystem offering high touchpoints for consumers across insurance, pharmacy, and virtual care.

With an ecosystem offering engagement points for consumers across insurance, Medicare, pharmacy, and value-based care, the company now has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, SelectPatient Management, a provider of chronic care management services, and Healthcare Select which proactively connects consumers with a wide breadth of healthcare services supporting their needs.

Investor Relations:
Sloan Bohlen
877-678-4083
investorrelations@selectquote.com

Media:
Matt Gunter
913-286-4931
matt.gunter@selectquote.com

Source: SelectQuote, Inc.

Can Warren Buffett’s Investment Style Be Applied to Small-Cap Stocks?

Posted on May 5, 2025May 6, 2025 by slightbourne@noblecapitalmarkets.com

Warren Buffett’s name is synonymous with long-term, value-based investing. His classic strategy — identifying quality companies with durable advantages and buying them at fair prices — has stood the test of time. But can this approach be adapted to today’s small-cap investing landscape?

The answer is yes — but with important modifications.

What Buffett’s Style Is All About

Buffett’s investment principles, especially in his early career, revolved around:

Buying high-quality businesses at undervalued or fair prices
Focusing on companies with strong returns on capital
Identifying durable competitive advantages (or “moats”)
Prioritizing capable and ethical management
Holding for the long term to allow value to compound

These timeless ideas can work well with small-cap companies — in fact, Buffett himself built much of his early wealth in this space.

Why Small-Caps Offer Unique Opportunities

Small-cap stocks are often overlooked and underfollowed by analysts, creating inefficiencies that patient, disciplined investors can exploit. Many of these companies operate in niche markets and still have room to grow, which means they may offer significantly higher upside potential than their large-cap counterparts.

What’s more, investors often have more direct access to management in small-caps, which enhances due diligence and helps gauge leadership quality — something Buffett emphasized early in his career.

But There Are Risks

Applying Buffett’s approach to small-caps also comes with new challenges:

Higher volatility: Small-caps are more sensitive to economic swings.
Weaker moats: Many are still building their competitive edge.
Limited financial history: Often, small-caps don’t have years of consistent performance to analyze.
Liquidity issues: Thin trading volumes can make it harder to enter or exit positions efficiently.

How to Adapt Buffett’s Style for Small-Cap Investing

To use Buffett’s playbook in the small-cap space, investors must tailor their approach:

Focus on management quality: In small companies, the CEO often is the business. Their vision and execution ability can make or break your investment.
Use a longer time horizon: Value in small-caps often takes time to be realized. Impatient investors are likely to miss out.
Demand a margin of safety: Given the risks, buying well below intrinsic value is essential.
Look for early moats: These might not be fully formed yet, but signs of customer loyalty, unique positioning, or intellectual property are promising indicators.
Stick to your circle of competence: Understanding the business and industry is even more critical when the data is sparse.

Final Thought

Buffett’s philosophy isn’t limited to blue-chip giants. In fact, it may shine brightest where the market is least efficient. The key to applying his principles to small-caps lies in disciplined research, patience, and a sharp eye for leadership. If you’re willing to do the work, small-cap investing — Buffett-style — can be a powerful path to wealth.

Release – The ONE Group Hospitality, Inc. to Host First Quarter 2025 Earnings Conference Call and Webcast at 4:30 PM ET on May 7, 2025

Posted on May 5, 2025May 5, 2025 by aweinsoff@channelchek.com

Research News and Market Data on STKS

May 05, 2025

Download as PDF

DENVER–(BUSINESS WIRE)– The ONE Group Hospitality, Inc. (“The ONE Group” or the “Company”) (Nasdaq: STKS) today announced that Emanuel “Manny” Hilario, President and Chief Executive Officer, and Tyler Loy, Chief Financial Officer, will host a conference call and webcast to discuss first quarter 2025 financial results on Wednesday, May 7, 2025 at 4:30 PM ET. A press release containing the first quarter 2025 financial results will be issued after market close that same afternoon.

The conference call can be accessed live over the phone by dialing 412-542-4186. A replay will be available after the call and can be accessed by dialing 412-317-6671; the passcode is 10198138. The replay will be available until Wednesday, May 21, 2025.

The webcast can be accessed from the Investor Relations tab of The ONE Group’s website at www.togrp.com under “News / Events”.

About The ONE Group

The ONE Group Hospitality, Inc. (Nasdaq: STKS) is an international restaurant company that develops and operates upscale and polished casual, high-energy restaurants and lounges and provides hospitality management services for hotels, casinos and other high-end venues both in the U.S. and internationally. The ONE Group’s focus is to be the global leader in Vibe Dining, and its primary restaurant brands and operations are:

STK, a modern twist on the American steakhouse concept with restaurants in major metropolitan cities in the U.S., Europe and the Middle East, featuring premium steaks, seafood and specialty cocktails in an energetic upscale atmosphere.
Benihana, an interactive dining destination with highly skilled chefs preparing food right in front of guests and served in an energetic atmosphere alongside fresh sushi and innovative cocktails. The Company franchises Benihanas in the U.S., Caribbean, Central America, and South America.
Kona Grill, a polished casual, bar-centric grill concept with restaurants in the U.S., featuring American favorites, award-winning sushi, and specialty cocktails in an upscale casual atmosphere.
RA Sushi, a Japanese cuisine concept that offers a fun-filled, bar-forward, upbeat, and vibrant dining atmosphere with restaurants in the U.S. anchored by creative sushi, inventive drinks, and outstanding service.
Salt Water Social is your gateway to the seven seas, featuring an array of signature and unique fresh seafood items, complemented by the highest quality beef dishes and elegant, delicious cocktails.
Samurai, an interactive dining experience located in sunny Miami, FL and soon to be in Westwood, CA, provides a distinctive dining experience where skilled personal chefs masterfully perform the ancient art of teppanyaki, anywhere from two to twenty tables, right before your eyes along with a robust selection of steak offerings.
ONE Hospitality, The ONE Group’s food and beverage hospitality services business develops, manages and operates premier restaurants and turnkey food and beverage services within high-end hotels and casinos currently operating venues in the U.S. and Europe.

Additional information about The ONE Group can be found at www.togrp.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250505203134/en/

Investors:
ICR
Michelle Michalski or Raphael Gross
(646) 277-1224
Michelle.Michalski@icrinc.com

Media:
ICR
Seth Grugle
(646) 277-1272
seth.grugle@icrinc.com

Source: The ONE Group Hospitality, Inc.

Released May 5, 2025

Release – GoHealth to Announce First Quarter 2025 Results on May 13, 2025

Posted on May 5, 2025May 5, 2025 by aweinsoff@channelchek.com

Research News and Market Data on GOCO

May 05, 2025 at 9:00 AM EDT

CHICAGO, May 05, 2025 (GLOBE NEWSWIRE) — GoHealth, Inc. (GoHealth) (NASDAQ: GOCO), a leading health insurance marketplace and Medicare-focused digital health company, announced that the company will release its first quarter 2025 financial results on the morning of May 13, 2025.

Chief Executive Officer, Vijay Kotte, and Chief Financial Officer, Brendan Shanahan, will host a conference call and live audio webcast on the day of the release at 8:00 a.m. (ET) to discuss the results.

A live audio webcast of the conference call will be available via GoHealth’s Investor Relations website, https://investors.gohealth.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call.

About GoHealth, Inc.

GoHealth is a leading health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers’ peace of mind when making healthcare decisions so they can focus on living life. For many of these consumers, enrolling in a health insurance plan is confusing and difficult, and seemingly small differences between health plans may lead to significant out-of-pocket costs or lack of access to critical providers and medicines. GoHealth’s proprietary technology platform leverages modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer’s specific needs. Its unbiased, technology-driven marketplace coupled with highly skilled licensed agents has facilitated the enrollment of millions of consumers in Medicare plans since GoHealth’s inception. For more information, visit https://www.gohealth.com.

Investor Relations
John Shave
jshave@gohealth.com

Media Relations
Pressinquiries@gohealth.com

Release – FAT Brands Announces Drew Martin as Chief Information Officer

Posted on May 5, 2025May 5, 2025 by aweinsoff@channelchek.com

Research News and Market Data on FAT

05/05/2025

Download(opens in new window)

Global Restaurant Franchising Company Hires Seasoned Global IT Executive

LOS ANGELES, May 05, 2025 (GLOBE NEWSWIRE) — FAT (Fresh. Authentic. Tasty.) Brands Inc., announces the hiring of Drew Martin as Chief Information Officer. Martin joins FAT Brands with over 35 years of IT experience, delivering impactful results for a wide range of companies—from Fortune 500 companies to high-growth start-ups. Martin will be focused on delivering scalable technological solutions to progress the growth of FAT Brands.

Martin’s diverse background includes serving as Senior Vice President and CIO for Jack in the Box and Senior Vice President and CIO for Sony Electronics. Other previous ventures include PepsiCo, leading the digital transformation/supporting the sale of Jenny Craig, and serving as Executive Vice President and CIO of high-growth software start-up Lytx Inc., where Martin led the development of AI product features.

“Drew’s vast experience across the consumer landscape will provide great value to FAT Brands as we continue to enhance and strengthen our technology platforms,” said Thayer Wiederhorn, Chief Operating Officer of FAT Brands. “His deep understanding of digital innovation will be instrumental as we work to elevate our guest experience, streamline operations, and drive long-term growth across our portfolio of brands.”

“FAT Brands continues to cement itself as a leader in the restaurant space with its dynamic, growing restaurant portfolio,” said Drew Martin, CIO of FAT Brands. “I look forward to identifying new technology opportunities that provide strategic value across our brands and position the company as an innovator within the industry.”

For more information on FAT Brands, visit www.fatbrands.com.

About FAT (Fresh. Authentic. Tasty.) Brands

FAT Brands (NASDAQ: FAT) is a leading global franchising company that strategically acquires, markets and develops fast casual, quick-service, casual and polished casual dining restaurant concepts around the world. The Company currently owns 18 restaurant brands: Round Table Pizza, Fatburger, Marble Slab Creamery, Johnny Rockets, Fazoli’s, Twin Peaks, Great American Cookies, Smokey Bones, Hot Dog on a Stick, Buffalo’s Cafe & Express, Hurricane Grill & Wings, Pretzelmaker, Elevation Burger, Native Grill & Wings, Yalla Mediterranean and Ponderosa and Bonanza Steakhouses, and franchises and owns over 2,300 units worldwide. For more information on FAT Brands, please visit www.fatbrands.com.

MEDIA CONTACT:
Erin Mandzik, FAT Brands
emandzik@fatbrands.com
860-212-6509

Source: FAT Brands Inc.

Vince Holding Corp. (VNCE) – Near Term Tariff Turbulence Likely

Posted on May 5, 2025May 5, 2025 by cpereira@noblefcm.com

Monday, May 05, 2025

500 5th Avenue 20th Floor New York, NY 10110 United States Sector(s): Consumer Cyclical Industry: Apparel Manufacturing Full Time Employees: 599 Key Executives Name Title Pay Exercised Year Born Mr. Jonathan CEO & Director 825.62k N/A 1958 Ms. Marie Fogel Senior VP and Chief Merchandising & Manufacturing Officer 633.19k N/A 1961 Mr. John Chief Financial Officer

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Favorable Fourth Quarter Results. Fourth quarter total company revenues increased an attractive 6.2% to $79.95 million, well above our $71.5 million estimate, primarily due to strong growth in its Wholesale business. Due to price integrity, gross margins substantially improved 470 basis points to 50.1%. As a result, adj. EBITDA in the latest quarter was $3.58 million, better than our $1.5 million estimate.

Adjusting estimates lower. Management guided fiscal first quarter revenues to be down 5%, with gross margins likely down 500 basis points. Notably, the first quarter guidance did not reflect the current U.S. trade policy. While the full extent of the company’s tariff mitigation plans are fluid, we believe that there will be some adverse revenue and cost of goods impact.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

ACCO Brands (ACCO) – Post Call Commentary

Posted on May 5, 2025May 5, 2025 by cpereira@noblefcm.com

Monday, May 05, 2025

ACCO Brands Corporation is one of the world’s largest designers, marketers and manufacturers of branded academic, consumer and business products. Our widely recognized brands include AT-A-GLANCE®, Esselte®, Five Star®, GBC®, Kensington®, Leitz®, Mead®, PowerA®, Quartet®, Rapid®, Rexel®, Swingline®, Tilibra®, and many others. Our products are sold in more than 100 countries around the world. More information about ACCO Brands, the Home of Great Brands Built by Great People, can be found at www.accobrands.com.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Control What Can Be Controlled. Given the uncertain economic situation, management is focused on what they can control. The prime examples being the multi-year cost out program and the effort to move manufacturing for U.S. based consumption to the lowest cost geographical areas possible. Management also continues to push forward its new product program to capture additional sales.

Cost Reduction Program. ACCO’s $100 million cost reduction program remains on track, with SG&A costs down y-o-y primarily due to the program. Management estimates some $7 million of savings during 1Q25, and the Company remains on track to deliver $40 million of savings in 2025. This will help alleviate some of the pressure from tariff uncertainty.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

April Jobs Report Shows Labor Market Holds Strong Despite Tariff Turbulence

Posted on May 5, 2025May 5, 2025 by slightbourne@noblecapitalmarkets.com

Key Points:
– The U.S. added 177,000 jobs in April, beating expectations and holding the unemployment rate steady at 4.2%.
– Wage growth slowed slightly, easing pressure on the Federal Reserve amid ongoing inflation concerns.
– Tariff impacts on jobs may not be fully visible yet, but early signs suggest employers are holding steady.

The U.S. labor market showed surprising resilience in April, even in the wake of President Trump’s sweeping “Liberation Day” tariffs that unsettled financial markets and raised fears of economic slowdown. According to the Bureau of Labor Statistics, the U.S. economy added 177,000 nonfarm payroll jobs last month, beating economists’ expectations of 138,000. The unemployment rate remained unchanged at 4.2%, maintaining stability in the face of mounting trade and inflation concerns.

Wage growth was slightly softer than anticipated, with average hourly earnings rising 0.2% over the prior month and 3.8% year-over-year. While these figures were modestly below forecasts, they suggest continued income gains without reigniting inflationary pressure — a welcome balance for policymakers and investors alike.

Markets responded positively to the data. Major indexes rose in early Friday trading, as investors interpreted the report as a sign that the economy may weather the storm from Trump’s tariff strategy better than initially feared. The CME FedWatch Tool showed reduced expectations for an immediate rate cut, easing pressure on the Federal Reserve to act in response to short-term volatility.

Sector-Level Trends Highlight Economic Rebalancing

A closer look at industry-level data reveals both strength and shifting dynamics within the labor market. Healthcare once again proved to be a cornerstone of job creation, adding 51,000 positions in April. The transportation and warehousing sector also saw a notable rebound, gaining 29,000 jobs after a sluggish March, possibly linked to pre-tariff import activity that boosted freight demand.

The leisure and hospitality sector, which has seen uneven recovery since the pandemic, added 24,000 jobs, signaling that consumer demand for services remains strong. However, federal government employment fell by 9,000 amid ongoing changes tied to the Trump administration’s Department of Government Efficiency (DOGE) initiative. Overall government hiring, including state and local positions, rose by 10,000.

Revisions to March’s job gains showed a slight decline, with the updated total now at 185,000, down from the previously reported 228,000. Still, the broader trend remains steady: the U.S. has averaged 152,000 job additions per month over the past year — enough to sustain growth without overheating the economy.

Timing Matters in Evaluating Tariff Impact

While Friday’s data offered a reassuring picture, economists caution that it may not fully capture the impact of the April 2 tariff announcement. Because payroll data is based on employment status during the pay period including the 12th of the month, many businesses may not have had time to implement layoffs or hiring freezes in response to the policy shift.

Still, early indicators suggest employers have not moved swiftly to cut staff. Initial jobless claims, while ticking up slightly in late April, remain relatively low. Private sector hiring data from ADP showed only 62,000 new jobs in April, the lowest since last July, suggesting a possible lag in response from employers.

Outlook for Small and Micro-Cap Investors

For investors focused on small and micro-cap stocks, April’s labor report offers a cautiously optimistic signal. Employment strength — especially in transportation, healthcare, and services — supports consumer demand and business stability. However, uncertainty tied to trade policy and inflation remains a risk factor. As the second quarter unfolds, close attention to hiring trends, inflation data, and Fed decisions will be critical for navigating market volatility and spotting growth opportunities.

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

Posted on May 2, 2025May 2, 2025 by slightbourne@noblecapitalmarkets.com

Research News and Market Data on Ocugen

MALVERN, Pa., May 02, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s first quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, May 9, 2025.

Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details:

Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID: 1773288
Webcast: Available on the events section of the Ocugen investor site

A replay of the call and archived webcast will be available for approximately 45 days following the event on the Ocugen investor site.

About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com

GeoVax Labs (GOVX) – 1Q25 Reported With Pipeline Strategy Updates

Posted on May 2, 2025May 2, 2025 by cpereira@noblefcm.com

Friday, May 02, 2025

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

First Quarter Included Contract Revenues. GeoVax reported a 1Q25 loss of $5.4 million or $(0.45) per share, a smaller loss than we had expected. The quarter included $1.6 million in Contract Revenue from the BARDA contract in preparation for the Phase 2 trial. Since the contract was cancelled on April 11, 2025, the 2Q25 results will include some final contract work. Cash on March 31, 2025, was $7.4 million.

CM04S1 Continues Development With Focus On Immunocompromised Patients. The current focus of CM04S1 development is in immunocompromised patients, a population estimated at 40 million patients in the US alone. Data from the Phase 1 and Phase 2 clinical trials for CM04S1 was presented at the 25^th World Vaccine Congress. The two Phase 2 trials in chronic lymphocytic leukemia and stem cell transplants continue to enroll patients, while the Phase 2 Healthy Adult Booster trial is expected to report data during 2Q25.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).